missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SEZ6L Polyclonal Antibody
Sheep Polyclonal Antibody
Brand: Invitrogen™ PA5148906
This item is not returnable.
View return policy
Description
Reconstitute with sterile PBS to a final concentration of 0.2 mg/mL.
SEZ6L (seizure related 6 homolog-like) is a 1,024 amino acid single-pass type I membrane protein that localizes to the endoplasmic reticulum. Widely expressed, SEZ6L is a candidate tumor suppressor gene and may contribute to specialized endoplasmic reticulum functions in neurons. SEZ6L contains three CUB domains and five sushi (CCP/SCR) domains, which may be involved in protein-protein interactions and signal transduction. The gene encoding SEZ6L is located on human chromosome 22, which houses over 500 genes and is the second smallest human chromosome. Mutations in several of the genes that map to chromosome 22 are involved in the development of Phelan-McDermid syndrome, Neurofibromatosis type 2, autism and schizophrenia.
Specifications
| SEZ6L | |
| Polyclonal | |
| Unconjugated | |
| SEZ6L | |
| Acig1; acupuncture induced gene 1; acupuncture-induced protein 1-L; AI843918; AIG1; Aig1l; AW539724; Brain-specific receptor-like protein B; BSRP-B; KIAA0927; mKIAA0927; RGD1563628; seizure 6-like protein; seizure related 6 homolog (mouse)-like; seizure related 6 homolog like; seizure related gene 6-like; Sez6l; UNQ2542/PRO6094 | |
| Sheep | |
| Antigen affinity chromatography | |
| RUO | |
| 56747 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Lyophilized |
| Immunohistochemistry (Frozen) | |
| 0.2 mg/mL | |
| PBS with trehalose and no preservative | |
| Q6P1D5 | |
| SEZ6L | |
| Mouse myeloma cell line NS0-derived recombinant mouse SEZ6L, Glu32-Ser889. | |
| 100 μg | |
| Primary | |
| Mouse | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction